Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m

Nephron - Clinical Practice

Volumn 120, Issue 4, 2012, Pages

  Fafin, C ^a   Pugliese, P ^a   Durant, J ^a   Mondain, V ^a   Rahelinirina, V ^a   De Salvador, F ^a   Ceppi, C ^a   Perbost, I ^a   Rosenthal, E ^a   Roger, P M ^a   Cua, E ^a   Dellamonica, P ^a   Esnault, V ^a   Pradier, C ^a   Moranne, O ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Antiretroviral treatment; Chronic kidney disease; Estimated glomerular filtration rate; Tenofovir

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATAZANAVIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDINAVIR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECTS; HIV INFECTIONS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; RISK FACTOR; TIME;

ADENINE; ANTI-HIV AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RISK FACTORS; TIME FACTORS;

EID: 84866926138     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000342377     Document Type: Article

References (50)

1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS: CONTINUED improvement in survival among HIV-Infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-692. (Pubitemid 46568625)
2. Selik RM, Byers RH, Jr., Dworkin MS: TRENDS in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29: 378-387. (Pubitemid 34288892)
3. Eggers PW, Kimmel PL: IS there an epidemic of HIV infection in the US ESRD program? J Am Soc Nephrol 2004; 15: 2477-2485. (Pubitemid 39159349)
4. Phillips AN, Neaton J, Lundgren JD: THE role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 2409-2418.
5. Hessamfar-Bonarek M, Morlat P, Salmon D, Cacoub P, May T, Bonnet F, Rosenthal E, Costagliola D, Lewden C, Chene G: CAUSES of death in HIV-Infected women: Persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19). Int J Epidemiol 2010; 39: 135-146.
6. Ross MJ, Klotman PE: RECENT progress in HIV-Associated nephropathy. J Am Soc Nephrol 2002; 13: 2997-3004. (Pubitemid 35386920)
7. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD: HIGHLY active antiretroviral therapy and the incidence of HIV-1-Associated nephropathy: A 12-year cohort study. AIDS 2004; 18: 541-546. (Pubitemid 38365883)
8. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD: END-stage renal disease and chronic kidney disease in a cohort of African-American HIV-Infected and at-Risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007; 21: 2435-2443. (Pubitemid 350145175)
9. Rachakonda AK, Kimmel PL: ckd in HIVinfected patients other than HIV-Associated nephropathy. Adv Chronic Kidney Dis 2010; 17: 83-93.
10. Winston JA: hiv and CKD epidemiology. Adv Chronic Kidney Dis 2010; 17: 19-25.
11. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, et al: THE safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007; 21: 1273-1281. (Pubitemid 46883481)
12. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, Telenti A: CHANGES in renal function associated with indinavir. AIDS 1998; 12:F249-F254. (Pubitemid 28558592)
13. Vigano A, Rombola G, Barbiano di Belgioioso G, Sala N, Principi N: SUBTLE occurrence of indinavir-Induced acute renal insufficiency. AIDS 1998; 12: 954-955. (Pubitemid 28241412)
14. Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF: INCIDENCE and etiology of acute renal failure among ambulatory HIV-Infected patients. Kidney Int 2005; 67: 1526-1531. (Pubitemid 40463131)
15. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD: CHRONIC renal failure among HIV-1-Infected patients. AIDS 2007; 21: 1119-1127. (Pubitemid 46763282)
16. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD: ESTIMATED glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678.
17. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S: GREATER tenofovir-Associated renal function decline with protease inhibitorbased versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108. (Pubitemid 351263473)
18. Leport C, Bouteloup V, Rossert J, Garre M, Iordache L, Dellamonica P, Herson S, Raffi F, Chene G: LONG-Term evolution and determinants of renal function in HIV-Infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. Clin Infect Dis 2009; 49: 1950-1954.
19. Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabie A, Poizot-Martin I, Katlama C, Brunet-Francois C, Yazdanpanah Y, et al: RISK factors of chronic kidney disease in HIV-Infected patients. Clin J Am Soc Nephrol 2011; 6: 1700-1707.
20. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, et al: ANTIRETROVIRAL treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
21. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: EFFICACY and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201. (Pubitemid 38917996)
22. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G: LONG-Term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-Infected patients. Data from a double-blind randomized active-Controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-746. (Pubitemid 40520651)
23. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, et al: TENOFOVIR disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78. (Pubitemid 351619372)
24. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM: TENOFOVIR-Related nephrotoxicity in human immunodeficiency virus-Infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-1073. (Pubitemid 36513295)
25. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, et al: RANDOMIZED comparison of renal effects, efficacy, and safety with once-Daily abacavir/ lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-Infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49-57.
26. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M: SYSTEMATIC review and meta-Analysis: Renal safety of tenofovir disoproxil fumarate in HIV-Infected patients. Clin Infect Dis 2010; 51: 496-505.
27. Kearney BP, Flaherty JF, Shah J: TENOFOVIR disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612. (Pubitemid 38951802)
28. Olmscheid B: IMPORTANT renal safety information regarding the use of Viread and Truvada. Dear Dr. Letter 2006.
29. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M: RELATIONSHIP between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 2011; 25: 1603-1609.
30. Pugliese P, Cuzin L, Cabie A, Poizot-Martin I, Allavena C, Duvivier C, El Guedj M, de la Tribonniere X, Valantin MA, Dellamonica P: A large French prospective cohort of HIVinfected patients: The NADIS cohort. HIV Med 2009; 10: 504-511.
31. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: DEFINITION and classification of chronic kidney disease: A position statement from Kidney Disease: IMPROVING Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
32. Levey AS, Greene T, Kusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11:A0828.
33. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
34. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH: IMPACT of missing data due to selective dropouts in cohort studies and clinical trials. Epidemiology 2002; 13: 347-355. (Pubitemid 34415857)
35. Laird NM, Ware JH: RANDOM-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
36. K/DOQI: CLINICAL practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 SUPPL1):S1-S266.
37. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek JW, Landis R, et al: A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1332-1338.
38. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen MH, Peters MG, Golub ET, Szczech L: HEPATITIS C seropositivity and kidney function decline among women with HIV: Data from the Women's Interagency HIV Study. Am J Kidney Dis 2009; 54: 43-50.
39. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J: CHANGE in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 2009; 20: 2617-2624.
40. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: CHRONIC kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
41. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG: KIDNEY function and the risk of cardiovascular events in HIV-1-Infected patients. AIDS 2010; 24: 387-394.
42. Alves TP, Hulgan T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA: RACE, kidney disease progression, and mortality risk in HIV-Infected persons. Clin J Am Soc Nephrol 2010; 5: 2269-2275.
43. Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M: CIDOFOVIR-Induced end-stage renal failure. Clin Infect Dis 1999; 29: 948-949. (Pubitemid 30256406)
44. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE: INHIBITION of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ ABCC3 by nucleoside, nucleotide, and nonnucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35: 340-344.
45. Rodriguez-Novoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di Perri G, et al: IMPAIRMENT in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064-1066.
46. Dabrowska M, Mikula T, Stanczak W, Malyszko J, Wiercinska-Drapalo A: COMPARATIVE analysis of the new CKD epidemiology collaboration and the modification of diet in renal disease equations for estimation of glomerular filtration rate in HIV-1-Infected subjects. AIDS Res Hum Retroviruses 2011; 27: 809-813.
47. Gagneux-Brunon A, Mariat C, Delanaye P: CYSTATIN C in HIV-Infected patients: Promising but not yet ready for prime time. Nephrol Dial Transplant 2012; 27: 1305-1313.
48. van Deventer HE, George JA, Paiker JE, Becker PJ, Katz IJ: ESTIMATING glomerular filtration rate in black South Africans by use of the modification of diet in renal disease and Cockcroft-Gault equations. Clin Chem 2008; 54: 1197-1202. (Pubitemid 352009697)
49. van Deventer HE, Paiker JE, Katz IJ, George JA: A comparison of cystatin C- And creatinine-based prediction equations for the estimation of glomerular filtration rate in black South Africans. Nephrol Dial Transplant 2011; 26: 1553-1558.
50. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG: ASSOCIATION of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-875.